ClinicalTrials.gg
Not yet recruitingNCT07859059Updated Oct 5, 2026

Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma

A Phase 1/2 interventional study of Dexbrompheniramine and Temozolomide in High Grade Glioma, Glioblastoma and Gliosarcoma, sponsored by University of Nebraska. Not yet recruiting at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Nebraska · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.

Planned enrollment
51st of 104
41 · median 41
Started
2027
with 1 other
Phase 1/2
17 of 112
5 open now
Primary completion
2030-06
later than 16 of 17 live
Registered
106th of 112
by date

Among the 112 studies testing temozolomide in Glioma, this one is the 51st largest by planned enrollment of the 104 interventional ones that give a count, is one of 2 that started in 2027, is one of 17 in phase 1/2, reaches primary completion later than 16 of the 17 other live ones, and was the 106th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies testing temozolomide in Glioma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to: 1) evaluate the safety, tolerability, and recommended dose of dexbrompheniramine when combined with metronomic temozolomide for adults with recurrent high-grade glioma who have been previously treated with standard of care chemoradiation therapy and 2) determine the efficacy of the combination therapy in adults with glioblastoma who progressed during the first six cycles of adjuvant standard dose temozolomide.

The main questions it aims to answer are:

  • What medical problems to participants have when taking dexbrompheniramine together with temozolomide?
  • What is the correct dose of dexbrompheniramine to use when evaluating the safety and efficacy of the combination therapy?
  • Is the combination therapy more effective at delaying disease progression compared to temozolomide alone?

Participants will take dexbrompheniramine and temozolomide every day at night.

03

Conditions studied

  • High Grade Glioma
  • Glioblastoma
  • Gliosarcoma

Keywords

  • Recurrent
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Phase I)

  1. proven diagnosis of high grade (aka grade 3 or 4) glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma).
  2. Patients must have received prior radiation therapy and standard temozolomide. Patients who have received any number of additional therapies for previous progressions will be considered eligible. Use of concurrent Optune is allowed.

Inclusion Criteria (Phase II)

1. Proven glioblastoma/gliosarcoma (2021 WHO criteria) that progressed after standard chemoradiation within the first six cycles of adjuvant TMZ.

Inclusion Criteria (Both Phases)

  1. Must be three or more months from the end of chemoradiotherapy or have or imaging consistent with disease progression.
  2. Age ≥ 19 years of age
  3. Recovery from toxicity of any prior therapy that in the opinion of the investigator could impact tolerance to the study drug.
  4. Adequate performance status: ≤ 2
  5. Adequate organ function:

    • bone marrow reserve: ( ≥ 1,500 mm3, ≥ 8 g/dL, count ≥ 100,000 mm3
    • renal function: (serum creatinine ≤ 2.0 mg/dL)
    • hepatic function: serum and ALT \< 1.5 , serum alkaline phosphatase \< 2.5 ULN)
  6. Women of must be non-pregnant and non-nursing. (non child bearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries) A negative pregnancy test is required within 7 days of initiating the study
  7. Both men and women must agree to employ an effective barrier method of throughout the study and for either 3 months (males) or 6 months (females) after the last treatment dose.
  8. Patients must willingly provide written, after being informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.

Exclusion Criteria

  1. Any significant illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral dexbrompheniramine, or put the study outcomes at undue risk.
  2. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification
  3. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  4. Immunotherapy, chemotherapy, radiotherapy, (at dosages equivalent to prednisone > 20 mg/day) or experimental therapy within 4 weeks before the first dose of study drug
  5. Any other active other than nonmelanoma skin cancer or controlled prostate cancer
  6. Lactating or pregnant
  7. Known history of intolerance to antihistamines due to glaucoma or urinary retention
  8. Ongoing treatment with MAO inhibitors. If MOAI medications can be safely stopped, a of at least 2 weeks is required prior to starting dexbrompheniramine
  9. Planned concomitant use of CNS depressants, including alcohol, that represent a risk to subject safety or study outcomes per the determination of the principal investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    Arm I: Dose Finding

    Participants receive daily dexbrompheniramine (either 4 mg, 6 mg, or 8 mg) together with 50mg/m2/day temozolomide for up to one year or until progression or intolerance.

    Drug: Dexbrompheniramine · Drug: Temozolomide

  • Experimental
    Arm II: Treatment

    Participants receive daily dexbrompheniramine at the recommended phase 2 dose together with 50mg/m2/day temozolomide for up to one year or until progression or intolerance.

    Drug: Dexbrompheniramine · Drug: Temozolomide

Interventions

  • DrugDexbrompheniramine

    Antihistamine, HRH1 antagonist

    Also known as: ALA-HIST-IR

  • DNA Alkylating Agent

    Also known as: Temodar

06

What researchers measure

Primary outcomes

  1. Safety and RP2D of Combination Therapy

    Evaluate toxicity and determine the recommended dose of dexbrompheniramine with metronomic temozolomide in subjects with recurrent grade 3 and grade 4 glioma.

    Time frame: 24 months

  2. Efficacy (PFS) of Combination Therapy

    Evaluate efficacy (PFS) of the recommended dose of dexbrompheniramine with metronomic temozolomide in subjects with glioblastoma/gliosarcoma who progress during their first six cycles of adjuvant standard dose temozolomide. (Phase II)

    Time frame: 48 months

Secondary outcomes

  1. To measure blood concentration of dexbrompheniramine with temozolomide

    Characterize pharmacokinetics (PK) of dexbrompheniramine with temozolomide in combination (Phase I) Population PK analyses will be used to estimate PK parameters for subjects with available PK sample collection, as means, SDs, medians, minimums, and maximums.

    Time frame: 24 months

  2. Efficacy (PFS, OS, TTF)

    Estimate progression free survival at 6 and 12 months, overall survival, and time to treatment failure (Both Phases).

    Time frame: 48 months

  3. Examine quality of life changes using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30.)

    Examine Quality of Life (QOL) using EORTC QLQ-C30 (Both Phases). EORTC QLQ-C30 will be summarized descriptively at each time point measured with mean, SD, median, and ranges in the intent-to-treat analysis set. Changes within subject over time will be graphically displayed with profile plots.

    Time frame: 48 months

  4. Tumor Response (RANO).

    Measure tumor response to treatment using RANO criteria (Both Phases)

    Time frame: 48 months

  5. Correlative Studies- Next Generation Sequencing (NGS)

    Correlate molecular profiles NGS and HRH1 expression with treatment outcomes. We will correlate molecular profiles (next generation sequencing) with tumor response as sample size allows, by dose level and overall. We will determine if changes in molecular profiles are associated with response using Kruskal-Wallis test or Wilcoxon rank sum test depending on the number of response categories. Expression levels will be correlated with each other using scatterplots and Spearman correlation. Mutational status will be assessed with frequency and percentage for each response category. Fisher's exact test will be used to determine whether there is an association between common mutations and response.

    Time frame: 48 months

  6. Correlative Studies- MGMT Status

    Correlate molecular profiles MGM and HRH1 expression with treatment outcomes. We will correlate molecular profiles (MGMT) with tumor response as sample size allows, by dose level and overall. We will determine if changes in molecular profiles are associated with response using Kruskal-Wallis test or Wilcoxon rank sum test depending on the number of response categories. Expression levels will be correlated with each other using scatterplots and Spearman correlation. Mutational status will be assessed with frequency and percentage for each response category. Fisher's exact test will be used to determine whether there is an association between common mutations and response.

    Time frame: 48 months

  7. Biological Changes-Exosome HRH1

    Evaluate changes in exosome HRH1 during treatment.

    Time frame: 48 months

  8. Biological Changes-Ki67cells

    Evaluate changes in Ki67 during treatment. The focused analysis will be done on the Ki67 cells in pre and post D-Brom dosage and levels associated with OS and PFS. Specifically, the Kaplan-Meier method will estimate OS and PFS distributions by median levels of Ki67 cells, pre-Brom dosage, with comparisons using the log-rank test. Cox regression will also consider Ki67 cellsas a time varying covariate (using the 3 time points collected) of OS and PFS. These analyses will be done by dose level and separately for the window of opportunity study (if sample size allows).

    Time frame: 48 months

  9. Biological Changes-CD8

    Evaluate changes in CD8 during treatment. The focused analysis will be done on the CD8 cells in pre and post D-Brom dosage and levels associated with OS and PFS. Specifically, the Kaplan-Meier method will estimate OS and PFS distributions by median levels of CD8 cells, pre-Brom dosage, with comparisons using the log-rank test. Cox regression will also consider CD8 cells as a time varying covariate (using the 3 time points collected) of OS and PFS. These analyses will be done by dose level and separately for the window of opportunity study (if sample size allows).

    Time frame: 48 months

  10. Biological Changes-T Cells

    Evaluate changes in T-Cells during treatment. The focused analysis will be done on the T cells in pre and post D-Brom dosage and levels associated with OS and PFS. Specifically, the Kaplan-Meier method will estimate OS and PFS distributions by median levels of T cells, pre-Brom dosage, with comparisons using the log-rank test. Cox regression will also consider T cells as a time varying covariate (using the 3 time points collected) of OS and PFS. These analyses will be done by dose level and separately for the window of opportunity study (if sample size allows).

    Time frame: 48 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Jun 2030, 36 months later.

Of 45 non-industry phase 1/2 interventional studies under Glioma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 104. This study's planned 36 months is below that.

Counting every sponsor, half of 71 studies reached it within 66 months; a quarter within 48 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Oct 5, 2026
StartEst.
Jun 1, 2027
Primary completionEst.
Jun 1, 2030
CompletionEst.
Jun 1, 2031
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859059
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Jun 1, 2027 (estimated)
Primary completion
Jun 1, 2030 (estimated)
Completion
Jun 1, 2031 (estimated)
Last update
Oct 5, 2026

Study contacts

IIT Office
Contact
IITOffice@unmc.edu
402-559-4596
Taylor A Johnson, MA
Contact
taylora.johnson@unmc.edu
402-559-4596
Nicole A Shonka, MD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion